{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:27:56Z","timestamp":1774981676271,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"s75","license":[{"start":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T00:00:00Z","timestamp":1040256000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:p>Urticaria is defined by weals (hives), with or without angioedema, that appear and peak in minutes to hours, usually disappear within 24\u2003h, and are accompanied by pruritus that worsens during the night. Urticaria is caused by cutaneous mast cell degranulation, attributed to immunological, nonimmunological, and idiopathic causes. Chronic idiopathic urticaria (CIU) is the diagnosis when the pathophysiological mechanism of persistent urticaria remains unclear; up to half of patients with CIU have functional autoantibodies directed against the high\u2010affinity receptor for IgE (<jats:italic>Fc\u03b5<\/jats:italic>RI) or against IgE itself, which appear to induce mast cell degranulation. Systemic histamine H<jats:sub>1<\/jats:sub>\u2010receptor antagonists, such as desloratadine, are central to the management of CIU. The efficacy and safety of desloratadine, 5\u2003mg once daily, was studied in a double\u2010blind, randomized, placebo\u2010controlled, multicentre trial that included 190 patients, ages 12 and above, with at least a 6\u2010week history of CIU and experiencing a flare of at least moderate severity. Desloratadine was superior to placebo in controlling pruritus and total symptoms after the first dose, and its superiority was maintained throughout the full 6\u2003weeks of the study. Measures of sleep, daily activity, therapeutic response, and global CIU status were also significantly improved with desloratadine after the first dose and maintained throughout the study.<\/jats:p>","DOI":"10.1034\/j.1398-9995.57.s75.4.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T01:51:23Z","timestamp":1047347483000},"page":"19-24","source":"Crossref","is-referenced-by-count":19,"title":["Chronic urticaria: impact of allergic inflammation"],"prefix":"10.1111","volume":"57","author":[{"given":"R.","family":"Hein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,12,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.00006.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02767.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104680"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.00023.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.114239"},{"key":"e_1_2_7_8_2","article-title":"Therapeutic points of intervention and clinical implications: role of desloratadine","author":"Bachert C","year":"2002","journal-title":"Clin Exp Immunol"},{"issue":"73","key":"e_1_2_7_9_2","first-page":"307","article-title":"Desloratadine regulates the expression of MHC\u2010class molecules and costimulatory signals in cultured human keratinocytes","volume":"57","author":"M\u00fcnster I","year":"2002","journal-title":"Allergy"},{"key":"e_1_2_7_10_2","article-title":"Anti\u2010inflammatory activity of desloratadine: a pilot study","author":"Reuther T","year":"2002","journal-title":"Poster abstract presented at 20th World Congress of Dermatology, 4\u20135 July"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb04983.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102030-00004"},{"key":"e_1_2_7_13_2","first-page":"181","article-title":"Drug\u2010induced urticaria","volume":"11","author":"Cousin F","year":"2001","journal-title":"Eur J Dermatol"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70273-V"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2000.105706"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/AC.2000.6347"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63071-2"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00780.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.20.2417"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02707.x"},{"key":"e_1_2_7_22_2","first-page":"16","article-title":"Are autoantibodies present in patients with subacute and chronic urticaria?","volume":"11","author":"Ryhal B","year":"2001","journal-title":"J Invest Clin Immunol"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70495-0"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000235301"},{"key":"e_1_2_7_25_2","first-page":"342","article-title":"Successful treatment of chronic idiopathic urticaria associated with thyroid autoimmunity","volume":"10","author":"Gaig P","year":"2000","journal-title":"J Invest Allergol Clin Immunol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2500\/108854101778250625"},{"key":"e_1_2_7_27_2","first-page":"521","article-title":"The diagnosis and management of urticaria: a practice parameter. Part I. Acute urticaria\/angioedema. Part II. Chronic urticaria\/angioedema","volume":"85","author":"Joint Task Force on Practice Parameters.","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(82)70139-2"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(92)70069-R"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200102010-00005"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040050-00009"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.00186.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1980.tb07912.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1982.tb01040.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00974-1"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03664.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02033.x"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1398-9995.57.s75.4.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1398-9995.57.s75.4.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:15:18Z","timestamp":1695726918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1398-9995.57.s75.4.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":36,"journal-issue":{"issue":"s75","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1034\/j.1398-9995.57.s75.4.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1398-9995.57.s75.4.x","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}